Lung Cancer Cells Have an Opioid Tumor-Suppression System That Smoking Nicotine Disables
Opioid peptides naturally inhibit lung cancer cell growth through all three receptor types, but nicotine at smoker blood-level concentrations reverses this protection in most cell lines.
Quick Facts
What This Study Found
Lung cancer cells have an opioid-based growth suppression system that nicotine can override. All three opioid receptor types participate, and the cancer cells produce their own opioid peptides.
Key Numbers
How They Did This
Receptor binding with specific radioligands, cAMP measurements, in vitro growth assays with opioid agonists and nicotine, and immunohistochemistry for opioid peptides in lung cancer cell lines.
Why This Research Matters
This suggests the body has a natural opioid-based defense against lung cancer growth that smoking disables. It provides a biological mechanism linking smoking to accelerated cancer progression.
The Bigger Picture
This study proposed a novel biological mechanism linking smoking to cancer progression. If the body uses opioid peptides as natural tumor suppressors and nicotine disables this system, it adds a new dimension to understanding why smoking causes and worsens lung cancer. It also raises the possibility of opioid-based cancer therapies.
What This Study Doesn't Tell Us
In-vitro study using cell lines. In vivo tumor biology involves many additional factors. The opioid growth inhibition effect needs confirmation in animal models and human tumors.
Questions This Raises
- ?Could opioid agonists be developed as anti-cancer agents for lung cancer?
- ?Does this opioid tumor-suppression system operate in other cancer types?
- ?Do endogenous opioid peptide levels predict lung cancer risk?
Trust & Context
- Key Stat:
- Nicotine reversed opioid protection in 9/14 cell lines At concentrations found in smokers' blood, nicotine disabled the opioid-mediated tumor growth suppression system
- Evidence Grade:
- Moderate in-vitro study across 14 diverse lung cancer cell lines with multiple receptor and growth assays. Compelling but needs in-vivo validation.
- Study Age:
- Published in 1990. The concept of opioid-mediated tumor suppression has been explored further, though opioid-cancer interactions remain complex and not fully resolved.
- Original Title:
- Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines.
- Published In:
- Proceedings of the National Academy of Sciences of the United States of America, 87(9), 3294-8 (1990)
- Authors:
- Maneckjee, R, Minna, J D(2)
- Database ID:
- RPEP-00164
Evidence Hierarchy
Frequently Asked Questions
How do opioid peptides suppress tumor growth?
Lung cancer cells produce their own opioid peptides that bind to opioid receptors on their surface. This activates signaling pathways that slow cell growth — a natural negative feedback loop. The cancer cells are essentially trying to slow their own growth.
Why does nicotine reverse this protection?
Nicotine activates nicotinic receptors on cancer cells that counteract the opioid growth-inhibition signal. At concentrations typical in smokers' blood, nicotine partially or completely overrides the opioid defense system, removing a natural brake on tumor growth.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00164APA
Maneckjee, R; Minna, J D. (1990). Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines.. Proceedings of the National Academy of Sciences of the United States of America, 87(9), 3294-8.
MLA
Maneckjee, R, et al. "Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines.." Proceedings of the National Academy of Sciences of the United States of America, 1990.
RethinkPeptides
RethinkPeptides Research Database. "Opioid and nicotine receptors affect growth regulation of hu..." RPEP-00164. Retrieved from https://rethinkpeptides.com/research/maneckjee-1990-opioid-and-nicotine-receptors
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.